Warberg Asset Management’s Regentis Biomaterials RGNT Stock Holding History

Warberg Asset Management’s Portfolio RGNT Stock Details RGNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$109K	Sell	58,526 -28,454	-33%	-$63.4K	0.01%	145
2026 Q2	$306K	Buy	+86,980	New	+$248K	0.06%	99
2026 Q1	–	Sell	-19,093	Closed	-$127K	–	235
2025 Q4	$127K	Buy	+19,093	New	+$131K	0.02%	134

Warberg Asset Management's RGNT Position: Q3 2026 in Review

Warberg Asset Management reduced its Regentis Biomaterials (RGNT) stake by 33% in Q3 2026, selling an estimated $63.4K and leaving 58,526 shares worth $109K. The position accounts for 0.01% of the portfolio, ranked #145.

Warberg Asset Management first reported a position in RGNT in Q4 2025 and has held it in 3 quarters since. The position peaked at $306K in Q2 2026. 1 fund tracked by Wall St. Rank holds RGNT as of Q3 2026.

Warberg Asset Management held 58,526 shares of Regentis Biomaterials worth $109K as of Q3 2026.
Warberg Asset Management sold 28,454 Regentis Biomaterials shares in Q3 2026, an estimated $63.4K.
Regentis Biomaterials made up 0.01% of Warberg Asset Management's portfolio in Q3 2026, its #145 holding.
Warberg Asset Management first reported a position in Regentis Biomaterials in Q4 2025 and has held it in 3 quarters since.
Warberg Asset Management's Regentis Biomaterials position peaked at $306K in Q2 2026.
1 fund tracked by Wall St. Rank held Regentis Biomaterials as of Q3 2026.

Based on Warberg Asset Management's 13F filing for Q3 2026, filed 2 Nov 2026.